TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

RHHBY

Roche Holding Ltd ADR

OTCQXCommon Stock
$53.08
+1.01%today

No SEC filings for this security

Roche Holding Ltd ADR is a foreign or OTC-listed security (OTCQX) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$36.42 – $58.72
36.4252-week58.72
Market cap
$342B
Volume
201K
1Y return
+33.85%
Beta
0.34

Price · 1Y

$53.08▲ +33.85%
over 1Y
L $36.42H $58.72

Recent news

market news →
Roche Reports Positive Results From Head-to-Head Study on NSCLC DrugBullish
finance.yahoo.com· 2026-07-03
Will Briumvi's Strength Continue to Aid TGTX's Top Line in Q2?Bullish
finance.yahoo.com· 2026-07-03
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.Bullish
nasdaq.com· 2026-07-02
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.Bullish
finance.yahoo.com· 2026-07-02
Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung CancerBullish
finance.yahoo.com· 2026-07-02
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancerBullish
finance.yahoo.com· 2026-07-02
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancerBullish
globenewswire.com· 2026-07-02
Roche (SWX:ROP) Stock May Still Be A Bargain On A 32% RunBullish
finance.yahoo.com· 2026-07-02

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.